Investigational treatments for multiple myeloma
| Autor: | Mario Boccadoro, Valeria Magarotto, Ilaria Avonto, Antonio Palumbo, Sara Bringhen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
MAPK/ERK pathway medicine.drug_class Antineoplastic Agents Drug resistance Pharmacology Monoclonal antibody Bortezomib Risk Factors Antineoplastic Combined Chemotherapy Protocols medicine Humans Protease Inhibitors Pharmacology (medical) Multiple myeloma PI3K/AKT/mTOR pathway Aged Lenalidomide Salvage Therapy Clinical Trials as Topic business.industry Remission Induction Antibodies Monoclonal Drugs Investigational General Medicine Middle Aged medicine.disease Boronic Acids Thalidomide Treatment Outcome Drug Resistance Neoplasm Drug Design Pyrazines Cancer research Female Multiple Myeloma business Proteasome Inhibitors medicine.drug |
| Zdroj: | Expert Opinion on Investigational Drugs. 15:1565-1582 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1517/13543784.15.12.1565 |
| Popis: | Multiple myeloma remains a fatal neoplasm and new treatments are urgently needed. In recent years, advances in understanding the molecular pathophysiology of myeloma and the mechanisms of drug resistance led to the development of several novel agents. The drugs with the most available clinical data are thalidomide, bortezomib and lenalidomide. Impressive results obtained with these agents - both in relapsed disease and in newly diagnosed patients - have significantly improved the outcome of myeloma patients. Several other new targeted agents are presently under investigation. These include monoclonal antibodies, agents that target mammalian target of rapamycin, histone acetylation, heat-shock proteins, growth factor signalling cascades, oncogenes, signal transducer and activators of the transcription pathway, Akt pathway and MAPK pathway. Their mechanisms of action, the available knowledge on their efficacy, safety and possible future clinical application are reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|